<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Awai A</submitter><funding>NIH G-RISE</funding><funding>NIGMS NIH HHS</funding><pagination>9234</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12470382</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>26(18)</volume><pubmed_abstract>Amyotrophic lateral sclerosis (ALS) is a terminal neurodegenerative disease, marked by considerable clinical and molecular heterogeneity. While several genetic drivers have been linked to familial ALS (fALS), the biology of sporadic ALS (sALS)-which accounts for the majority of ALS cases-remains poorly defined. To address this gap, we analyzed 247 bulk mRNA-sequenced post-mortem tissue samples from the lumbar spinal cord and motor cortex and compared expression profiles between fALS, sALS, and controls. Variance-stabilized DEGs from DESeq2 analysis were used as inputs for weighted gene co-expression network analysis (WGCNA). Finally, gene ontology was used to identify transcriptomic signatures and biological pathways unique to sALS and fALS. In the spinal cord, sALS samples exhibited speci</pubmed_abstract><journal>International journal of molecular sciences</journal><pubmed_title>Stratifying ALS Patients by Mode of Inheritance Reveals Transcriptomic Signatures Specific to sALS and fALS.</pubmed_title><pmcid>PMC12470382</pmcid><funding_grant_id>R25GM058268.</funding_grant_id><funding_grant_id>R25 GM058268</funding_grant_id><pubmed_authors>On Behalf Of The Nygc Als Consortium</pubmed_authors><pubmed_authors>Leng T</pubmed_authors><pubmed_authors>Patrickson J</pubmed_authors><pubmed_authors>Awai A</pubmed_authors><pubmed_authors>Johnson EL</pubmed_authors><pubmed_authors>Lillard JW</pubmed_authors><pubmed_authors>Zody MC</pubmed_authors></additional><is_claimable>false</is_claimable><name>Stratifying ALS Patients by Mode of Inheritance Reveals Transcriptomic Signatures Specific to sALS and fALS.</name><description>Amyotrophic lateral sclerosis (ALS) is a terminal neurodegenerative disease, marked by considerable clinical and molecular heterogeneity. While several genetic drivers have been linked to familial ALS (fALS), the biology of sporadic ALS (sALS)-which accounts for the majority of ALS cases-remains poorly defined. To address this gap, we analyzed 247 bulk mRNA-sequenced post-mortem tissue samples from the lumbar spinal cord and motor cortex and compared expression profiles between fALS, sALS, and controls. Variance-stabilized DEGs from DESeq2 analysis were used as inputs for weighted gene co-expression network analysis (WGCNA). Finally, gene ontology was used to identify transcriptomic signatures and biological pathways unique to sALS and fALS. In the spinal cord, sALS samples exhibited speci</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Sep</publication><modification>2026-05-02T03:09:51.467Z</modification><creation>2026-05-02T03:07:38.205Z</creation></dates><accession>S-EPMC12470382</accession><cross_references><pubmed>41009796</pubmed><doi>10.3390/ijms26189234</doi></cross_references></HashMap>